KLRA
KLRA
Kailera Therapeutics, Inc.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $84.66M | $-78.86M | 0% | $-0.67 | $-84.56M |
What's going well?
The company has a strong focus on research and development, investing $70.9 million in potential future products. No interest or tax burden gives flexibility if revenue arrives.
What's concerning?
There is no revenue, and expenses are very high, leading to a $78.9 million loss. The lack of sales and ongoing heavy spending raise questions about sustainability.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $519.17M | $624.76M | $1.06B | $-432.09M |
What's financially strong about this company?
KLRA is sitting on over $519 million in cash and short-term investments, far more than its near-term bills. Debt is very low, and assets are mostly real and liquid.
What are the financial risks or weaknesses?
The company has negative equity, meaning it owes more than it owns, and has a long history of losses. This is a serious red flag for investors.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-78.86M | $-68.31M | $22.85M | $-2.98M | $-48.44M | $-68.31M |
What's strong about this company's cash flow?
The company still has over $112 million in cash, and working capital changes helped cash flow this quarter. No debt means no interest burden.
What are the cash flow concerns?
Operations are burning through $68 million in cash each quarter, and free cash flow is negative. With no revenue or capital investment, the company will need to raise more money soon if losses continue.
5-Year Trend Analysis
A comprehensive look at Kailera Therapeutics, Inc.'s financial evolution and strategic trajectory over the past five years.
Kailera combines a sizable cash position, minimal traditional debt, and a concentrated R&D effort in one of the most attractive therapeutic markets today. Its partnership with Jiangsu Hengrui provides both scientific and capital efficiency benefits, while its diversified pipeline of injectable and oral obesity drugs offers multiple shots on goal. Operationally, the company has already scaled its development infrastructure, positioning it to run global late‑stage trials and, potentially, to transition to commercialization.
The main risks are classic for a late‑stage biotech but amplified by the competitive context: no current revenue, large ongoing losses, negative free cash flow, and a balance sheet with heavy accumulated deficits and negative equity. Kailera is heavily dependent on successful clinical outcomes, regulatory approvals, and favorable reimbursement decisions in a market dominated by powerful incumbents. High cash burn means that setbacks in trials or financing markets could pressure its runway and bargaining power in future partnerships or capital raises.
Looking ahead, Kailera’s trajectory will be driven by the clinical and regulatory progress of its lead obesity programs and its ability to differentiate meaningfully in a crowded field. If late‑stage trials confirm superior efficacy or tolerability and the company can translate that into regulatory approvals and market access, its current financial losses could eventually flip into a scalable, high‑margin business. Until then, the story remains one of high potential but also high execution and financing risk, typical of a clinical‑stage biotech aiming to compete in a blockbuster category.
About Kailera Therapeutics, Inc.
www.kailera.comKailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $84.66M | $-78.86M | 0% | $-0.67 | $-84.56M |
What's going well?
The company has a strong focus on research and development, investing $70.9 million in potential future products. No interest or tax burden gives flexibility if revenue arrives.
What's concerning?
There is no revenue, and expenses are very high, leading to a $78.9 million loss. The lack of sales and ongoing heavy spending raise questions about sustainability.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $519.17M | $624.76M | $1.06B | $-432.09M |
What's financially strong about this company?
KLRA is sitting on over $519 million in cash and short-term investments, far more than its near-term bills. Debt is very low, and assets are mostly real and liquid.
What are the financial risks or weaknesses?
The company has negative equity, meaning it owes more than it owns, and has a long history of losses. This is a serious red flag for investors.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-78.86M | $-68.31M | $22.85M | $-2.98M | $-48.44M | $-68.31M |
What's strong about this company's cash flow?
The company still has over $112 million in cash, and working capital changes helped cash flow this quarter. No debt means no interest burden.
What are the cash flow concerns?
Operations are burning through $68 million in cash each quarter, and free cash flow is negative. With no revenue or capital investment, the company will need to raise more money soon if losses continue.
5-Year Trend Analysis
A comprehensive look at Kailera Therapeutics, Inc.'s financial evolution and strategic trajectory over the past five years.
Kailera combines a sizable cash position, minimal traditional debt, and a concentrated R&D effort in one of the most attractive therapeutic markets today. Its partnership with Jiangsu Hengrui provides both scientific and capital efficiency benefits, while its diversified pipeline of injectable and oral obesity drugs offers multiple shots on goal. Operationally, the company has already scaled its development infrastructure, positioning it to run global late‑stage trials and, potentially, to transition to commercialization.
The main risks are classic for a late‑stage biotech but amplified by the competitive context: no current revenue, large ongoing losses, negative free cash flow, and a balance sheet with heavy accumulated deficits and negative equity. Kailera is heavily dependent on successful clinical outcomes, regulatory approvals, and favorable reimbursement decisions in a market dominated by powerful incumbents. High cash burn means that setbacks in trials or financing markets could pressure its runway and bargaining power in future partnerships or capital raises.
Looking ahead, Kailera’s trajectory will be driven by the clinical and regulatory progress of its lead obesity programs and its ability to differentiate meaningfully in a crowded field. If late‑stage trials confirm superior efficacy or tolerability and the company can translate that into regulatory approvals and market access, its current financial losses could eventually flip into a scalable, high‑margin business. Until then, the story remains one of high potential but also high execution and financing risk, typical of a clinical‑stage biotech aiming to compete in a blockbuster category.
CEO
Ronald C. Renaud Jr.
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 71
Ratings Snapshot
Rating : C